ReNeuron

As a pioneer in stem cell therapies, investors recognise that ReNeuron is now translating exciting stem cell science into biopharmaceutical products to treat serious disease conditions such as stroke, where the patient populations are large and where patients have few if any alternative treatments available to them. Buchanan’s close working relationship with the ReNeuron team led to high profile and positive media coverage as the Company conducted a ground-breaking first-in-man clinical trial of ReN001, its stem cell therapy for the treatment of patients left disabled by the effects of a stroke late in 2010. Buchanan continues to raise ReNeuron’s profile with investors and media as one of the most exciting, cutting edge UK life sciences companies today.